Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
The patients took Vivotif second and third capsules two days in a row; Case reference number US-BN-2025-000402 is a spontaneous case initially received from other health professional via Communication (reference number: USBAV25-0667) on 25-Mar-2025 and concerns two patients 60-year-old female and 69-year-old male patient. The patient's medical history and concomitant medication details were not provided. On 21-Mar-2025, the patients took first dose of Vivotif vaccine (batch number: unknown), at an unknown dose, orally, for indication reported as pre-travel. On 23-Mar-2025, two days after the first dose, the patients took second dose of Vivotif vaccine (batch number: unknown), at an unknown dose, orally. On 24-Mar-2025, three days after the first dose, reported as two doses in a row, the patient took third dose of Vivotif vaccine (batch number: unknown), at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse events due to Vivotif. Additional information received from other health professional via Med Communication (reference number: USBAV25-0670) on 25-Mar-2025 included: demographics information for addtional reporter.; Reporter's Comments: This case report concerns two patients; 60-year-old female and 69-year-old male patient. Three days after the first dose, reported as two doses in a row, the patient took third dose of Vivotif vaccine, at an unknown dose, orally which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: This case report concerns two patients; 60-year-old female and 69-year-old male patient. Three days after the first dose, reported as two doses in a row, the patient took third dose of Vivotif vaccine, at an unknown dose, orally which is considered as inappropriate schedule of vaccine administered. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse events due to Vivotif. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None